Welcome Guest | Register / Login

MP Advisors Market Research Reports

Sort By
Title Published Price Buy Now
Therapy Class Overview : Hepatitis C Virus Infection
By MP Advisors
Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gilead&rs...
Oct 2015 $ 1000
India Rising Stars Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there
By MP Advisors
Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there. However, there have a been a new generation of entrepreneurs who have who ventured into the drug discovery path backed...
Jan 2015 $ 1000
Dainippon Sumitomo Pharma - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable!
By MP Advisors
Dainippon Sumitomo (DSP) is one of those Japanese pharma companies which has changed its orbit by successful US launch of Latuda (Lurasidone, dopamine-2, serotonin-2 and serotonin-7 receptors agonist schizophrenia/bipolar disorder) in the last two...
Jan 2014 $ 500
Takeda , Challenges Ahead for its New European President
By MP Advisors
Post Nycomed and Millenium acquisition, the new leadership of non-Japanese CEO/President Mr. Weber will transform Takeda in a truly global Japanese company in the coming years. It is however important to see how he fulfills the Japanese expectatio...
Jan 2014 $ 500
MITSUBISHI TANABE , Outperform - Invokana: Nice to Have A Clean Label, Yet A Long Way To Go Before Gaining Full Confidence!
By MP Advisors
Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak. However we think that CV issues (dose dependent increase in LDL, CV events observed in first 30 days in CANVAS study), associated genital/...
Apr 2013 $ 500
VERTEX PHARMA - Dependence on Success of its CF Pipeline = Risk
By MP Advisors
Vertex Pharma - (VRTX) stock has moved up ~30% in this year mostly based on the positive expectation building on Lumacaftor/KALYDECO (CFTR corrector/ CFTR potentiator, PhIII, homozygous del508 mutation Cystic fibrosis/CF), after it received breakt...
Apr 2013 $ 140
RIGEL - SyK Inhibition Not Good Enough - Limited Market Potential!
By MP Advisors
RIGL/AZN's Fostamatinib (FosD, syk inhibitor, PhIII) has again disappointed by not demonstrating better or at par efficacy with approved or competing RA drugs. Despite achieving a statistically significant ACR20 improvement at 24 weeks in a PhIII,...
Apr 2013 $ 140
CADILA HEALTHCARE LTD, Upgrade to Outperform - Best Poised beyond Patent Cliff - Complex Generics launches on the horizon
By MP Advisors
We upgrade Cadila Healthcare to Outperform and increase price target from `815 to `1050, as we build into our model forecasts for its high margin / low competition opportunities (Mesalamine franchise, Trasnsdermal patches and Urokinase). We see Ca...
Apr 2013 $ 140
AstraZeneca - On the verge of a breakdown - Respiratory portfolio (Symbicort and Pulmicort) threatened by Generics
By MP Advisors
The respiratory portfolio of AZN which so far has withstood generics attack, is now giving away. Yesterday's court ruling invalidating pulmicort respule patent and Teva filing a MAA in Europe for a generic equivalent of Symbicort has really shaken...
Apr 2013 $ 90
BIOGEN IDEC - Hold On - After TECFIDERA Array of Approvals Yet to Come!
By MP Advisors
Most awaited approval of TECFIDERA (BG-12, delayed-release capsule of dimethyl fumerate) with a label should seal Biogen Idec (BIIB) - supremacy in the MS space. We expect TECFIDERA to become the first choice among oral MS drugs in the first line ...
Mar 2013 $ 140
TRIUS THERAPEUTICS - Partnering or Buy Out = Upside
By MP Advisors
Positive top line data of Tedizolid (oral/IV, 2nd-generation oxazolidinone, PhIII, Acute Bacterial Skin and Skin Structure Infections - ABSSSI; PhII, CAP/HAP/Bacteremia, partnered with Bayer for Asian, LA and ME rights) from 2nd pivotal PhIII stud...
Mar 2013 $ 90
Astellas, Acofide: Japanese Approval Raises Global Hopes!
By MP Advisors
Astellas and Zeria announced today that they received approval for Acofide in Japan (Acotiamide /Z-338, functional dyspepsia, jointly developed by Astellas and Zeria in Japan). Acofide is the first drug to be approved for Functional Dyspepsia (und...
Mar 2013 $ 90
Dolutegravir - SAILING data confirms best in class integrase inhibitor - More threat to Elvitegravir than Raltegravir
By MP Advisors
Dolutegravir - SAILING data confirms best in class integrase inhibitor - More threat to Elvitegravir than RaltegravirClinical data from PhIII SAILING study announced yesterday demonstrated dolutegravir - statistically significant superiority...
Mar 2013 $ 90
Competition for Pristiq - Earlier than Expected - A Substantial Opportunity for Alembic and Ranbaxy
By MP Advisors
Pfizer - Pristiq will now witness competition as today the USFDA approved Alembic - 505 (b) (2) application for Extended release Desvenlafaxine base tablets, which is bioequivalent to Pfizer - Pristiq (Desvenlafaxine Succinate). This novel version...
Mar 2013 $ 90
New Technologies Initiative: Gateway to Treating Genetic Diseases - Sarepta Therapeutics - Skipping Makes Sense - Restoring Muscle Function in Duchenne Muscular Dystrophy
By MP Advisors
Approval of KYNAMRO (ISIS/Sanofi, HoFH), a first systemic Oligonucleotide Antisense (ASO) based therapy has raised expectations from the compounds in pipeline of other companies with similar technology platforms.  Highly differentiate...
Mar 2013 $ 500
AMGEN - Dynamic Strategies in Place for Global Expansion of Innovative Drugs and Biosimilars = Growth Drivers
By MP Advisors
Amgen (AMGN) began 2013 on a positive note outlining long-term (post-2015) growth strategies through new product launches, global expansion, and entering the global biosimilar space with new partners and ventures.  Unexpected setback to Omont...
Feb 2013 $ 140
SYMBIO - Growth Driver: PI3K Inhibitor's Rigosertib & Cash to In-license More!
By MP Advisors
Disappointing guidance of TREAKISYM’s (bendamustine hydrochloride, L, rrNHL, MCL) sales for FY13 (¥1,927m de-growth of 1.4%) and discontinuation of TREAKISYM for refractory/relapsed aggressive non-Hodgkin’s Lymphoma (NHL) brought d...
Feb 2013 $ 140
NATCO PHARMA, Outperform - Major New Product Launches to strengthen growth Trajectory
By MP Advisors
We maintain our outperform rating on Natco Pharma as we expect robust growth in FY 14 driven by important new high potential launches (oncology space) in the domestic market. We are particularly excited about Everolimus launch (May 2013) in the do...
Feb 2013 $ 140
NOVO NORDISK , SANOFI - Tresiba and Ryzodeg delayed in the US: Lantus protected - Reduce PT to DKK 950
By MP Advisors
Post complete response letter issued by the USFDA to NOVOB for Tresiba and Ryzodeg, we reduce our PT for NOVOB from DKK 1000 to DKK 950. Considering the US constitutes the biggest long acting insulin market (Lantus-US sales: $4b; Western EU: $1.0b...
Feb 2013 $ 90
CURIS- Time to Assess Value Beyond Erivedge!
By MP Advisors
Oral PI3K, BTK, Bcl-2 inhibitors are set to bring a change in treatment paradigm of hematological malignancies (CLL, iNHL, ALL). Curis's (CRIS) pipeline consists of a marketed drug Erivedge (L in US, R in EU/other, vismodegib, HedgeHog pathway inh...
Feb 2013 $ 140
GLAXOSMITHKLINE - Novel Combo therapy (BRAF+MEK) filed in Europe - Potential New SoC for BRAF positive metastatic melanoma patients
By MP Advisors
GSK announced the filing of its BRAF and MEK inhibitors– trametinib (MEK inhibitor) as monotherapy and in combination with dabrafenib (BRAF inhibitor) as combo therapy for the treatment of metast...
Feb 2013 $ 90
GILEAD SCIENCES - New HIV + HCV Products to Sustain the Growth Trajectory
By MP Advisors
Initial sales of newly added HIV products - Complera/ Eviplera (L, truvada + rilpivirine), Stribild (L in US, R in EU, truvada+ cobicistat+ elvitegravir) along with growth in other marketed products contributed to the impressive 4Q12/FY13 results ...
Feb 2013 $ 140
BIOGEN IDEC - Restructuring of Tysabri Collaboration with ELAN - A Good Strategic Move!
By MP Advisors
Biogen Idec (BIIB) has acquired full rights to Tysabri from Elan for an upfront payment of $3.25b and a double-digit tiered royalty structure. Integrating this in our model the net positive impact to NPV/s of Tysabri is $9.4 (current NPV/s of Tysa...
Feb 2013 $ 140
Therapeutic Class Report Overview - Future Of GPR Agonist
By MP Advisors
Despite about half a dozen distinct targets having been innovated and introduced in the market for the oral treatment of Type 2 diabetes, ~60% of diabetics still exhibit progressive worsening of glycemic control and ~half of them end up with daily...
Feb 2013 $ 1000
Therapeutic Class Report Overview : Hepatitis C Virus Infection
By MP Advisors
The launch of Protease inhibitors’ (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raised the bar and the expectations of ...
Feb 2013 $ 1000